Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Allogeneic Stem Cell Transplant Recipient: early-phase trial registry
1 of 2 indexed Allogeneic Stem Cell Transplant Recipient trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Allogeneic Stem Cell Transplant Recipient: 2 US clinical trials tracked, 1 recruiting.
Allogeneic Stem Cell Transplant Recipient is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Sumithira Vasu, running 1 of these trials.
Enrollment posture brief
Registry condition allogeneic-stem-cell-transplant-recipient
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Allogeneic Stem Cell Transplant Recipient lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Allogeneic Stem Cell Transplant Recipient on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Allogeneic Stem Cell Transplant Recipient is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
Hackensack Meridian Health
NCT07214688
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
Sumithira Vasu
NCT04220684
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Allogeneic Stem Cell Transplant Recipient records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Allogeneic Stem Cell Transplant Recipient trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Allogeneic Stem Cell Transplant Recipient page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Allogeneic Stem Cell Transplant Recipient trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sumithira Vasu sponsors the most Allogeneic Stem Cell Transplant Recipient trials on record, review their full trial history before evaluating a specific study. See Sumithira Vasu's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Allogeneic Stem Cell Transplant Recipient condition card totals 2 registered trials; most-linked intervention Fludarabine; top US site state Oregon. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.